3.0.0 2376 2023-01-11T13:36:48Z 2023-01-11T13:36:48Z House HR 2017-05-04 115 [Congressional Record Volume 163, Number 77 (Thursday, May 4, 2017)]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. LANCE:H.R. 2376.Congress has the power to enact this legislation pursuantto the following:Article I, Section 8, Clause 18, which states that theCongress has the power to make all laws which shall benecessary and proper for carrying into execution theforegoing powers, and all other powers vested by thisConstitution in the government of the United States or in anydepartment or officer thereof.[Page H4179]]]> hsif00 Energy and Commerce Committee House Standing hsif14 Health Subcommittee Referred to 2017-05-05T20:23:45Z Referred to 2017-05-04T13:01:15Z FDA Reauthorization Act of 2017 115 2430 HR 2017-08-18 Signed by President. Related bill CRS FDA Reauthorization Act of 2017 115 934 S 2017-05-11 Placed on Senate Legislative Calendar under General Orders. Calendar No. 76. Related bill CRS 2017-05-05 hsif14 Health Subcommittee 1 House committee actions Referred to the Subcommittee on Health. Committee 2017-05-04 Referred to the House Committee on Energy and Commerce. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2017-05-04 Introduced in House IntroReferral Intro-H 9 Library of Congress 2017-05-04 Introduced in House IntroReferral 1000 9 Library of Congress L000567 Rep. Lance, Leonard [R-NJ-7] Leonard Lance R NJ 7 N D000624 Rep. Dingell, Debbie [D-MI-12] Debbie Dingell D MI 12 2017-05-04 True B001248 Rep. Burgess, Michael C. [R-TX-26] Michael Burgess R TX C. 26 2017-05-04 True G000410 Rep. Green, Gene [D-TX-29] GENE GREEN D TX 29 2017-05-04 True Health Consumer affairs Drug safety, medical device, and laboratory regulation Drug trafficking and controlled substances Fraud offenses and financial crimes Manufacturing Health 00 2017-05-04 Introduced in House 2019-04-15T22:32:23Z Drug Diversion and Counterfeit Crackdown Act of 2017

This bill makes it illegal except in cases of a drug shortage to import into the United States prescription drugs manufactured outside the United States and intended by the manufacturer or labeled to be marketed outside the United States.

The bill establishes a penalty for knowingly dispensing or selling a counterfeit drug.

]]> Drug Diversion and Counterfeit Crackdown Act of 2017 Display Title Drug Diversion and Counterfeit Crackdown Act of 2017 Official Title as Introduced To amend the Federal Food, Drug, and Cosmetic Act to protect and strengthen the drug supply chain in the United States by closing several statutory gaps in the penalty provisions of such Act that apply to drug diversion and counterfeiting. Introduced in House IH Short Titles as Introduced Drug Diversion and Counterfeit Crackdown Act of 2017 Introduced in House 2017-05-04T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-115hr2376ih/xml/BILLS-115hr2376ih.xml 2017-05-05 Referred to the Subcommittee on Health. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.